TransCode Therapeutics (RNAZ) announces an exclusive license for advanced cancer immunotherapy tech from Unleash, targeting hard-to-treat bladder cancer and more, in an all-stock deal to expand their pipeline.
CG Oncology announces earlier-than-expected results for its Phase 3 bladder cancer trial, moving timeline up by nearly one year due to rapid patient enrollment.
Raymond James upgrades enGene to Strong Buy with $27 target as detalimogene shows 62% complete response rate in bladder cancer trial with excellent tolerability.
Cretostimogene, a new bladder cancer treatment, shows durable 24-month complete responses (41.8%) in high-risk patients unresponsive to BCG. It has a good safety profile and offers bladder-sparing potential, with approval submission planned.
